Is ARIAD Pharmaceuticals, Inc. (ARIA) a Buy, Sell, or Hold?
NASDAQ : ARIA
ARIAD Pharmaceuticals, Inc.
$23.99 USD
$0.04 (0.17%)
- Volume
- 7.22M
- Average Volume
- 6.58M
- Market Capitalization
- $0
- P/E Ratio
- -19.83
- Dividend Yield
- 0.00%
- Price Target
- $33.00
- Year High
- $23.99
- Year Low
- $4.67
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.08
Company Overview
NASDAQ
None
Biotechnology
Healthcare
ARIA
N/A
None
USD
Liquidity Metrics
-0.71
2.08
2.07
1.75
0.00
Sales & Valuation
$118.8M
0.00
-44.40
0.00
-0.92
Profitability
-$1.21
-$231.16M
-194.57%
-197.43%
2069.44%
-42.28%
P/E Metrics
-19.83
-0.25
-0.25
Analyst Price Target & Rating
$33.00
$33.00
$33.00
0/5
0 Analysts
-27.30%
Financial Health Scores
No financial score data available.
Key Metrics (TTM)
-$157.86M
-1.33
0.78
2.08
2069.44%
-48.81%
-5.05%
%
-2700 days
Company Executives
No executive data available.
Poll Results
No votes yet today — be the first to share your view!
About ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) Stock
ARIAD Pharmaceuticals, Inc. operates as a global oncology firm, dedicated to the identification, advancement, and commercialization of innovative therapies. Its core mission is to significantly improve the lives of those affected by cancer. Leveraging an innovative methodology grounded in structure-based drug design, the company has successfully pioneered numerous precision-targeted treatments, particularly addressing malignancies that are resistant to existing therapies or are inherently challenging to manage. ...
Promis Reports No ARIA-E in PMN310 Alzheimer's Trial Interim Data
2026-07-28 14:05:07
Promis Neurosciences NASDAQ: PMN reported blinded six-month interim data from its Phase 1b PRECISE-AD trial of PMN310, an investigational antibody designed to selectively target toxic amyloid-beta oligomers in patients with mild cognitive impairment due to Alzheimer's disease and early Alzheimer's disease.
2026-07-14 10:00:00
[url="]Ionis Pharmaceuticals, Inc.[/url] (Nasdaq: IONS) today announced that its partner, Biogen, shared data from the Phase 2 CELIA study evaluating diranerse
2026-07-13 08:30:00
ARIA brings agentic AI execution to property management, leasing, compliance, accounting support, and customer engagement
2026-06-29 08:00:00
LIVINGSTON, N.J.--(BUSINESS WIRE)--CoreWeave, Inc. (Nasdaq: CRWV), The Essential Cloud for AI™, today announced the launch of CoreWeave ARIA (AI Research & Iteration Agent), an AI research agent built directly into Weights & Biases (W&B) by CoreWeave that reads experiment data, uncovers hidden insights, and drives continuous model and agent improvement. ARIA was built using W&B Weave, CoreWeave's agent development platform. W&B Weave's agent development capabilities also ent.
Frequently Asked Questions
-
What is the current ARIAD Pharmaceuticals, Inc. (ARIA) stock price?
-
ARIAD Pharmaceuticals, Inc.(NASDAQ:ARIA) stock price is $23.99 in the last trading session. During the trading session, ARIA stock reached the peak price of $4.67 while $23.99 was the lowest point it dropped to. The percentage change in ARIA stock occurred in the recent session was 0.17% while the dollar amount for the price change in ARIA stock was $0.04.
-
ARIA's industry and sector of operation?
-
The NASDAQ listed ARIA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ARIA?
-
|
|
|
|
| -
How many employees does ARIA have?
-
Number of ARIA employees currently stands at None. ARIA operates from None, None, None None, None.
-
Link for ARIA official website?
-
Official Website of ARIA is: None
-
How do I contact ARIA?
-
ARIA could be contacted at phone #None and can also be accessed through its website. ARIA operates from None, None, None None, None.
-
How many shares of ARIA are traded daily?
-
The average number of ARIA shares traded daily for last 3 months was 6.58M.
-
What is the market cap of ARIA currently?
-
The market value of ARIA currently stands at $0 with its latest stock price at $23.99